Brian Gadbaw

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

Suzanne Shusterman, Wendy B. London, Stephen D. Gillies et al. · Journal of Clinical Oncology · 2010 · 242 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Edward M. Wolin, Barbara Jarząb, Barbro Eriksson et al. · Drug Design Development and Therapy · 2015 · 208 citations · Full text

Medicine, Endocrinology, Oncology +17

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

David Delgado, Jacquelyn A. Hank, Jill Kolesar et al. · Cancer Research · 2010 · 176 citations · Full text

Life Sciences, Immunology, Oncology +17

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

Alessandro M. Vannucchi, Srđan Verstovšek, Paola Guglielmelli et al. · Annals of Hematology · 2017 · 96 citations · Full text

Medicine, Hematology, Pharmacology +7

Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH  Trials

Madan Jagasia, Robert Zeiser, Michael Arbushites et al. · Immunotherapy · 2018 · 94 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +15